1422051-33-9
1422051-33-9 structure
- Name: HAA-09
- Chemical Name: HAA-09
- CAS Number: 1422051-33-9
- Molecular Formula: C17H18F2N6O2
- Molecular Weight: 376.36
- Catalog: Signaling Pathways Anti-infection Influenza Virus
- Create Date: 2023-07-10 18:47:24
- Modify Date: 2025-09-01 12:06:07
-
HAA-09 is an orally active and potent anti-influenza agent, targeting the influenza PB2_cap binding domain. HAA-09 displays potent anti-influenza A virus activity, with an EC50 of 0.03 μM. HAA-09 shows polymerase inhibition, with an IC50 of 0.06±0.004 μM. HAA-09 blocks virus replication without causing obvious cytotoxicity[1].
| Name | HAA-09 |
|---|
| Description | HAA-09 is an orally active and potent anti-influenza agent, targeting the influenza PB2_cap binding domain. HAA-09 displays potent anti-influenza A virus activity, with an EC50 of 0.03 μM. HAA-09 shows polymerase inhibition, with an IC50 of 0.06±0.004 μM. HAA-09 blocks virus replication without causing obvious cytotoxicity[1]. |
|---|---|
| Related Catalog | |
| Target |
IC50: 0.06±0.004 μM (polymerase); EC50: 0.03 μM (influenza A virus)[1] |
| In Vitro | HAA-09 对奥司他韦 (oseltamivir) 敏感的 A/WSN/33 和奥司他韦耐药的 H275Y 变体表现出更强的抗病毒活性，优于奥司他韦[1]。 |
| In Vivo | HAA-09 具有较高的血浆稳定性(t1/2≥12 h)，且无明显的 hERG 抑制作用[1]。 HAA-09 (0-25 mg/kg; 口服; 每天两次) 在小鼠体内具有抗流感病毒作用[1]。 Animal Model: Balb/C mice[1] Dosage: 40 mg/kg Administration: Orally, QD (once daily) for consecutive 3 days Result: Demonstrated a favorable safety profile when orally administrated in healthy mice. Animal Model: Female BALB/c mice (6–8 weeks)[1] Dosage: 12.5, 25 mg/kg Administration: Orally, BID (twice daily) starting 48 h post infection for 9 days Result: Demonstrated in vivo therapeutic efficacy (85.7% survival observed at the day 15 post infection). |
| References |
| Molecular Formula | C17H18F2N6O2 |
|---|---|
| Molecular Weight | 376.36 |